Swiss pharma giant Roche (ROG: SIX) has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (faricimab) for the treatment of macular edema following retinal vein occlusion (RVO).
This is the third indication for Vabysmo, the first bispecific antibody approved for the eye. Previous approvals have been granted by the FDA to treat neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Together, the three retinal conditions affect around 70 million people worldwide, and they are among the leading causes of vision loss.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze